Skip to main content
SpringerLink
Log in

The Place of Phosphodiesterase Inhibitors in Acute Circulatory Failure

  • Conference paper
Update 1989

Part of the book series: Update in Intensive Care and Emergency Medicine ((UICM,volume 8))

Abstract

Phosphodiesterase (PDE) inhibitors are potent cardiotonic agents. The hemodynamic effects of amrinone, the first compound of this new class of drugs to be approved for clinical investigation were reported a decade ago [1]. Since then, many other PDE inhibitors have been introduced: some of them are now available for clinical use, depending on the countries: amrinone,milrinone, enoximone. Other PDE inhibitors are still under clinical investigation. Although they have mainly been reported in the treatment of severe congestive heart failure patients, they have also been successfully used in the management of various forms of acute circulatory failure.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Benotti JR, Grossman W, Braunwald E, et al (1978) Hemodynamic assessment of amrinone: A new inotropic agent. N Engl J Med 299:1373–1377

    Article  PubMed  CAS  Google Scholar 

  2. Kariya T, Dage RC (1988) Tissue distribution and selective inhibition of subtypes of high affinity cAMP phosphodiesterase. Biochemical Pharmacology 37:3267–3270

    Article  PubMed  CAS  Google Scholar 

  3. Colucci WS, Wright RF, Braunwald E (1986) New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. N Engl J Med 314:349–358

    Article  PubMed  CAS  Google Scholar 

  4. Herzig JW, Feile K, Ruegg JC (1981) Activating effects of AR-L 115 BS on the calcium sensitive force, stiffness and unloaded shortening velocity (V max) in isolated contractile structures from mammalian heart muscle. Arzneimittelforsch/Drug Res 31:188–191

    CAS  Google Scholar 

  5. Endoh M, Yanagisawa T, Taira N, et al (1986) Effects of new inotropic agents on cyclic nucleotide metabolism and calcium transients in canine ventricular muscle. Circulation (suppl 3) 73:117–123

    Google Scholar 

  6. Dage RC, Kariya T, Hsieh PC, et al (1987) Pharmacology of enoximone. Am J Cardiol 60:10C–5C

    Article  PubMed  CAS  Google Scholar 

  7. Cody RJ, Muller FB, Kubo SH, et al (1986) Identification of the direct vasodilator effects of milrinone with an isolated limb preparation in patients with chronic congestive heart failure. Circulation 73:124–129

    Article  PubMed  CAS  Google Scholar 

  8. Endoh M, Yamashita S, Taira N (1982) Positive inotropic effect of amrinone in relation to cyclic nucleotide metabolism in the canine ventricular muscle. J Pharmacol Exp Ther 221:775–780

    PubMed  CAS  Google Scholar 

  9. Dage RC, Roebel LE, Hsieh CP, et al (1982) Cardiovascular properties of a new cardiotonic agent: MDL 17,043 (l,3-dihydro-4-methyl-5-[4-(methylthio)-benzoyl]-2H-imidazol-2-one). J Cardiovasc Pharmacol 4:500–508

    Article  PubMed  CAS  Google Scholar 

  10. Roebel LE, Dage RC, Cheng HC, et al (1982) Characterization of the cardiovascular activities of a new cardiotonic agent, MDL 17,043 (13-dihydro-4-methyl-5-[4-(methylthio)-benzoyl]-2H-imidazol-2-one). J Cardiovasc Pharmacol 4:721–729

    Article  PubMed  CAS  Google Scholar 

  11. Crawford MH, Richards KL, Sodums MT, et al (1984) Positive inotropic and vasodilator effects of MDL 17,043 in patients with reduced left ventricular performance. Am J Cardiol 53:1051–1053

    Article  PubMed  CAS  Google Scholar 

  12. Kereiakes D, Chatterjee K, Parmley WW, et al (1984) Intravenous and oral MDL 17,043 (a new inotrope-vasodilator agent) in congestive heart failure: Hemodynamic and clinical evaluation in 38 patients. J Am Coll Cardiol 4:884–889

    Article  PubMed  CAS  Google Scholar 

  13. Colucci WS, Wright RF, Jaski BE, et al (1986) Milrinone and dobutamine in severe heart failure: Differing hemodynamic effects and individual patient responsiveness. Circulation (suppl 3) 73:175–183

    Google Scholar 

  14. Konstam MA, Cohen SR, Weiland DS, et al (1986) Relative contribution of inotropic and vasodilators effects to amrione-induced hemodynamic improvement in congestive heart failure. Am J Cardiol 57:242–248

    Article  PubMed  CAS  Google Scholar 

  15. Herrmann HC, Ruddy TC, Dec GW, et al (1987) Inotropic effect of enoximone in patients with severe heart failure: demonstration by left ventricular end-systolic pressure-volume analysis. J Am Coll Cardiol 9:1117–1123

    Article  PubMed  CAS  Google Scholar 

  16. Installé E, De Coster P, Gonzales M, et al (1989) Comparative effects of enoximone and dobutamine on left ventricular contractility in patients with moderate to severe congestive heart failure. A study using the end-systolic pressure-volume relationship method (submitted)

    Google Scholar 

  17. Ludmer PL, Wright RF, Arnold MO, et al (1986) Separation of the direct myocardial and vasodilator actions of milrinone administered by an intracoronary infusion technique. Circulation 73:130–137

    Article  PubMed  CAS  Google Scholar 

  18. Feldman MD, Copelas L, Gwathmey JK, et al (1987) Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation 75:331–339

    Article  PubMed  CAS  Google Scholar 

  19. Böhm M, Diet F, Kremkes B, et al (1988) Enhancement of the effectiveness of milrinone to increase force of contraction by stimulation of cardiac beta-adrenoreceptors in the failing human heart. Klin Wochenschr 66:957–962

    Article  PubMed  Google Scholar 

  20. Herrmann HC, Ruddy TD, Dec GW, et al (1987) Diastolic function in patients with severe heart failure: comparison of the effects of enoximone and nitroprusside. Circulation 75:1214–1221

    Article  PubMed  CAS  Google Scholar 

  21. Martin JL, Likoff MJ, Janicki JS, et al (1984) Myocardial energetics and clinical response to the cardiotonic agent MDL 17,043 in advanced heart failure. J Am Coll Cardiol 4:875–883

    Article  PubMed  CAS  Google Scholar 

  22. Jaski BE, Fifer MA, Wright RF, et al (1984) Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure: Dose-response relationships and comparison to nitroprusside. J Clin Invest 75:643–649

    Article  Google Scholar 

  23. Viquerat CE, Kereiakes D, Morris DL, et al (1985) Alterations in left ventricular function, coronary hemodynamics, and myocardial catecholamine balance with MDL 17,043: a new inotropic vasodilator agent in patients with severe heart failure. J Am Coll Cardiol 5:326–332

    Article  PubMed  CAS  Google Scholar 

  24. Weber KT, Janicki JS, Jain MC (1986) Piroximone (MDL 19,205) in the treatment of unstable and stable chronic cardiac failure. Am Heart J 114:805–813

    Article  Google Scholar 

  25. Uretsky BF, Valdes AM, Reddy PS (1986) Positive inotropic therapy for short-term support and long-term management of patients with congestive heart failure: hemodynamic effects and clinical efficacy of MDL 17,043. Circulation (suppl 3) 73:219–229

    Google Scholar 

  26. Monrad ES, Bairn DS, Smith HS, et al (1986) Milrinone, dobutamine and nitroprusside: Comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure. Circulation (suppl 3) 73:168–174

    Google Scholar 

  27. Installé E, Gonzales M, Jacquemart JL, et al (1987) Comparative effects on hemodynamics of enoximone (MDL 17,043), dobutamine and nitroprusside in severe congestive heart failure. Am J Cardiol 60:46C–2C

    Article  PubMed  Google Scholar 

  28. Gage J, Rutman H, Lucido D, et al (1986) Additive effects of dobutamine and amrinone on myocardial contractility and ventricular performance in patients with severe heart failure. Circulation 74:367–373

    Article  PubMed  CAS  Google Scholar 

  29. Uretsky BF, Lawless CE, Verbalis JG, et al (1987) Combined therapy with dobutamine and amrinone in severe heart failure: Improved hemodynamics and increased activation of the renin-angiotensin system with combined intravenous therapy. Chest 92:657–662

    Article  PubMed  CAS  Google Scholar 

  30. Gonzalez M, Desager JP, Jacquemart JL, et al (1988) Efficacy of enoximone in the management of refractory low-output states following cardiac surgery. J Cardiothoracic Anesthesia 2:409–418

    Article  CAS  Google Scholar 

  31. Vincent JL, Carlier E, Berré J, et al (1988) Administration of enoximone in cardiogenic shock. Am J Cardiol 62:419–423

    Article  PubMed  CAS  Google Scholar 

  32. Vincent JL, Goldstein J, Leeman M, et al (1984) Administration of sulmazol in low-output states following cardiac surgery. Chest 86:602–606

    Article  PubMed  CAS  Google Scholar 

  33. Goenen M, Pedemonte O, Baele P, et al (1985) Amrinone in the management of low cardiac output after open heart surgery. Am J Cardiol 56:33–38

    Article  Google Scholar 

  34. Vincent JL, Van Reeth O, Van Bogaert E, et al (1986) Use of the new inotropic agent ARL-115 BS to treat severe myocardial depression in septic shock. Crit Care Med 14:661–662

    Article  Google Scholar 

  35. Vincent JL, de Boelpaepe C, Luypaert P, et al (1988) Association of amrinone with norepinephrine in endotoxic shock in dogs: An experimental study. Crit Care Med 16:402

    Article  Google Scholar 

  36. Vincent JL, Domb M, Van der Linden P, et al (1988) Amrinone administration in endotoxic shock. Circ Shock 25:75–83

    PubMed  CAS  Google Scholar 

  37. Goenen M, Col J, Compere A, et al (1986) Treatment of severe verapamil poisoning with combined amrinone-isoproterenol therapy. Am J Cardiol 58:1142–1143

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. E. Installé
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Intensive Care Erasme Hospital, Free University of Brussels, Route de Lennik 808, B-1070, Brussels, Belgium

    Jean Louis Vincent (Clinical Director) (Clinical Director)

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Installé, E. (1989). The Place of Phosphodiesterase Inhibitors in Acute Circulatory Failure. In: Vincent, J.L. (eds) Update 1989. Update in Intensive Care and Emergency Medicine, vol 8. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-83737-1_62

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-83737-1_62

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-50879-3

  • Online ISBN: 978-3-642-83737-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation